3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
1
Pancreatic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
26
Capecitabine
16
Oxaliplatin
14
Fluorouracil
13
Cisplatin
12
Leucovorin
9
pembrolizumab
5
Erlotinib Hydrochloride
5
Bevacizumab
5
durvalumab
4
Trastuzumab
4
Specimen Handling
4
Sorafenib
4
Magnetic Resonance Spectroscopy
4
130-nm albumin-bound paclitaxel
4
trifluridine tipiracil drug combination
3
Lapatinib
3
Irinotecan
3
Carboplatin
3
Biopsy
3
tremelimumab
2
toripalimab
2
regorafenib
2
lenvatinib
2
dehydroftorafur
2
cobimetinib
2
atezolizumab
2
anlotinib
2
Nivolumab
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Gallbladder Neoplasms
×
Rivaroxaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled